MedRx（4586）株式概要製剤開発会社である株式会社メドレックスは、経皮吸収製剤に基づく医薬品を日本で提供している。 詳細4586 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6報酬過去5年間の収益は年間0.9%増加しました。 リスク分析収益が 100 万ドル未満 ( ¥131M )過去1年間で株主の希薄化が進んだ 意味のある時価総額がありません ( ¥3B )JP市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る4586 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW494,503 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG494,503 investors already sharing narrativesYour Fair ValueJP¥Current PriceJP¥53.00345.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-1b400m2016201920222025202620282031Revenue JP¥399.6mEarnings JP¥58.8mAdvancedSet Fair ValueView all narrativesMedRx Co., Ltd 競合他社Tsubota LaboratorySymbol: TSE:4890Market cap: JP¥6.2bNippon ChemipharSymbol: TSE:4539Market cap: JP¥5.6bPRISM BioLabLTDSymbol: TSE:206AMarket cap: JP¥5.2bRaQualia PharmaSymbol: TSE:4579Market cap: JP¥12.5b価格と性能株価の高値、安値、推移の概要MedRx過去の株価現在の株価JP¥53.0052週高値JP¥225.0052週安値JP¥48.00ベータ0.551ヶ月の変化-7.02%3ヶ月変化-35.37%1年変化-24.29%3年間の変化-67.08%5年間の変化-73.63%IPOからの変化-97.70%最新ニュースReported Earnings • May 20First quarter 2026 earnings released: JP¥4.01 loss per share (vs JP¥9.03 loss in 1Q 2025)First quarter 2026 results: JP¥4.01 loss per share (improved from JP¥9.03 loss in 1Q 2025). Net loss: JP¥238.0m (loss narrowed 45% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.New Risk • Mar 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (JP¥128m revenue, or US$813k). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.42b market cap, or US$47.2m).Reported Earnings • Feb 16Full year 2025 earnings released: JP¥17.44 loss per share (vs JP¥18.54 loss in FY 2024)Full year 2025 results: JP¥17.44 loss per share. Net loss: JP¥937.0m (loss widened 16% from FY 2024).お知らせ • Feb 13MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026.お知らせ • Dec 27MedRx Co., Ltd to Report Fiscal Year 2025 Results on Feb 13, 2026MedRx Co., Ltd announced that they will report fiscal year 2025 results on Feb 13, 2026分析記事 • Dec 01Is MedRx (TSE:4586) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...最新情報をもっと見るRecent updatesReported Earnings • May 20First quarter 2026 earnings released: JP¥4.01 loss per share (vs JP¥9.03 loss in 1Q 2025)First quarter 2026 results: JP¥4.01 loss per share (improved from JP¥9.03 loss in 1Q 2025). Net loss: JP¥238.0m (loss narrowed 45% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.New Risk • Mar 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (JP¥128m revenue, or US$813k). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.42b market cap, or US$47.2m).Reported Earnings • Feb 16Full year 2025 earnings released: JP¥17.44 loss per share (vs JP¥18.54 loss in FY 2024)Full year 2025 results: JP¥17.44 loss per share. Net loss: JP¥937.0m (loss widened 16% from FY 2024).お知らせ • Feb 13MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026.お知らせ • Dec 27MedRx Co., Ltd to Report Fiscal Year 2025 Results on Feb 13, 2026MedRx Co., Ltd announced that they will report fiscal year 2025 results on Feb 13, 2026分析記事 • Dec 01Is MedRx (TSE:4586) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...お知らせ • Oct 01MedRx Co., Ltd to Report Q3, 2025 Results on Nov 14, 2025MedRx Co., Ltd announced that they will report Q3, 2025 results on Nov 14, 2025New Risk • Aug 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (JP¥44m revenue, or US$298k). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (JP¥6.38b market cap, or US$43.3m).New Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (JP¥44m revenue, or US$300k). Minor Risk Market cap is less than US$100m (JP¥5.18b market cap, or US$35.3m).New Risk • Aug 10New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: JP¥44m (US$298k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (JP¥44m revenue, or US$298k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (JP¥3.42b market cap, or US$23.1m).New Risk • Jul 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.9% average weekly change). Minor Risks Revenue is less than US$5m (JP¥259m revenue, or US$1.8m). Market cap is less than US$100m (JP¥3.70b market cap, or US$25.2m).お知らせ • Jul 02MedRx Co., Ltd to Report Q2, 2025 Results on Aug 08, 2025MedRx Co., Ltd announced that they will report Q2, 2025 results on Aug 08, 2025お知らせ • Apr 16MedRx Co., Ltd announced that it has received ¥0.8309 million in fundingOn April 16, 2025, MedRx Co., Ltd closed the transaction.New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (JP¥257m revenue, or US$1.8m). Market cap is less than US$100m (JP¥2.71b market cap, or US$18.5m).お知らせ • Mar 28MedRx Co., Ltd to Report Q1, 2025 Results on May 09, 2025MedRx Co., Ltd announced that they will report Q1, 2025 results on May 09, 2025お知らせ • Mar 25MedRx Co., Ltd announced that it expects to receive ¥0.8309 million in fundingMEDRx Co., Ltd. announced a private placement to issue 118,700 units 32nd Series of Stock Acquisition Rights at an issue price of ¥7 per right for gross proceeds of ¥830,900 on March 25, 2025. The transaction will include participation from new investor Long Corridor Alpha Opportunities Master Fund. The transaction has been approved by shareholders, expected to close on April 16, 2025. The initial exercise price will be ¥86. The period will be from April 17, 2025 (inclusive) to April 23, 2026 (inclusive). The allocation will be made through a third-party allocation as follows: LCAO 94,960 units MAP 246 23,740 units. The company has disclosed the issue expenses of ¥12,000,000 and net proceeds of ¥1,009,650,900, total amount of payment of ¥1,021,650,900.Reported Earnings • Feb 16Full year 2024 earnings released: JP¥18.54 loss per share (vs JP¥26.80 loss in FY 2023)Full year 2024 results: JP¥18.54 loss per share (improved from JP¥26.80 loss in FY 2023). Revenue: JP¥257.0m (up JP¥228.0m from FY 2023). Net loss: JP¥806.0m (loss narrowed 14% from FY 2023). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Feb 14MedRx Co., Ltd, Annual General Meeting, Mar 28, 2025MedRx Co., Ltd, Annual General Meeting, Mar 28, 2025.お知らせ • Jan 03MedRx Co., Ltd to Report Fiscal Year 2024 Results on Feb 14, 2025MedRx Co., Ltd announced that they will report fiscal year 2024 results on Feb 14, 2025分析記事 • Sep 04Here's Why We're Not At All Concerned With MedRx's (TSE:4586) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Aug 31MedRx Co., Ltd to Report Q3, 2024 Results on Nov 08, 2024MedRx Co., Ltd announced that they will report Q3, 2024 results on Nov 08, 2024お知らせ • Jun 28MedRx Co., Ltd to Report Q2, 2024 Results on Aug 09, 2024MedRx Co., Ltd announced that they will report Q2, 2024 results on Aug 09, 2024分析記事 • May 13Companies Like MedRx (TSE:4586) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Reported Earnings • May 13First quarter 2024 earnings released: JP¥3.33 loss per share (vs JP¥9.59 loss in 1Q 2023)First quarter 2024 results: JP¥3.33 loss per share (improved from JP¥9.59 loss in 1Q 2023). Net loss: JP¥128.0m (loss narrowed 56% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • Apr 05MedRx Co., Ltd to Report Q1, 2024 Results on May 10, 2024MedRx Co., Ltd announced that they will report Q1, 2024 results on May 10, 2024お知らせ • Feb 11MedRx Co., Ltd, Annual General Meeting, Mar 28, 2024MedRx Co., Ltd, Annual General Meeting, Mar 28, 2024.お知らせ • Feb 06MedRx Co., Ltd announced that it has received ¥1.9076 million in funding from Evolution Capital Management LLCOn February 5, 2024, MedRx Co., Ltd, closed the transaction.お知らせ • Dec 28MedRx Co., Ltd to Report Fiscal Year 2023 Results on Feb 09, 2024MedRx Co., Ltd announced that they will report fiscal year 2023 results on Feb 09, 2024New Risk • Oct 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m (JP¥56m revenue, or US$374k). Minor Risk Market cap is less than US$100m (JP¥5.14b market cap, or US$34.4m).お知らせ • Oct 05MedRx Co., Ltd to Report Q3, 2023 Results on Nov 10, 2023MedRx Co., Ltd announced that they will report Q3, 2023 results on Nov 10, 2023New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Revenue is less than US$1m (JP¥56m revenue, or US$384k). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (43% increase in shares outstanding). Market cap is less than US$100m (JP¥6.27b market cap, or US$43.0m).Reported Earnings • Aug 12Second quarter 2023 earnings released: JP¥5.60 loss per share (vs JP¥7.52 loss in 2Q 2022)Second quarter 2023 results: JP¥5.60 loss per share. Net loss: JP¥191.0m (loss widened 3.2% from 2Q 2022).お知らせ • Jun 28MedRx Co., Ltd to Report Q2, 2023 Results on Aug 10, 2023MedRx Co., Ltd announced that they will report Q2, 2023 results on Aug 10, 2023Reported Earnings • May 17First quarter 2023 earnings released: JP¥9.59 loss per share (vs JP¥7.97 loss in 1Q 2022)First quarter 2023 results: JP¥9.59 loss per share (further deteriorated from JP¥7.97 loss in 1Q 2022). Net loss: JP¥290.0m (loss widened 48% from 1Q 2022). Revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 31Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: JP¥43.80 loss per share. Net loss: JP¥1.11b (loss widened 4.9% from FY 2021). Revenue missed analyst estimates by 82%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Japan.Reported Earnings • Feb 12Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: JP¥43.80 loss per share. Net loss: JP¥1.11b (loss widened 4.9% from FY 2021). Revenue missed analyst estimates by 82%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Pharmaceuticals industry in Japan.お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 29, 2023MedRx Co., Ltd, Annual General Meeting, Mar 29, 2023.お知らせ • Dec 28MedRx Co., Ltd to Report Fiscal Year 2022 Results on Feb 10, 2023MedRx Co., Ltd announced that they will report fiscal year 2022 results on Feb 10, 2023Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (6 non-independent directors). Independent External Director Kunio Iwatani was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 13Third quarter 2022 earnings released: JP¥10.32 loss per share (vs JP¥9.21 loss in 3Q 2021)Third quarter 2022 results: JP¥10.32 loss per share (further deteriorated from JP¥9.21 loss in 3Q 2021). Net loss: JP¥254.0m (loss widened 25% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • Sep 28MedRx Co., Ltd to Report Q3, 2022 Results on Nov 11, 2022MedRx Co., Ltd announced that they will report Q3, 2022 results on Nov 11, 2022お知らせ • Aug 24MedRx Co., Ltd announced that it expects to receive ¥3.904 million in fundingMedRx Co., Ltd announced a private placement of 61,000 series 24 warrants at a price of ¥64 each for gross proceeds of ¥3,904,000. The series 24 warrants at exercisable at a minimum price of ¥64.Reported Earnings • Aug 12Second quarter 2022 earnings released: JP¥7.52 loss per share (vs JP¥10.61 loss in 2Q 2021)Second quarter 2022 results: JP¥7.52 loss per share (up from JP¥10.61 loss in 2Q 2021). Net loss: JP¥185.0m (loss narrowed 12% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • May 30MedRx Co., Ltd to Report Q2, 2022 Results on Aug 10, 2022MedRx Co., Ltd announced that they will report Q2, 2022 results on Aug 10, 2022Reported Earnings • May 19First quarter 2022 earnings released: JP¥7.97 loss per share (vs JP¥13.32 loss in 1Q 2021)First quarter 2022 results: JP¥7.97 loss per share (up from JP¥13.32 loss in 1Q 2021). Net loss: JP¥196.0m (loss narrowed 25% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (6 non-independent directors). Independent External Director Kunio Iwatani was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 08MedRx Co., Ltd to Report Q1, 2022 Results on May 13, 2022MedRx Co., Ltd announced that they will report Q1, 2022 results on May 13, 2022お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 30, 2022MedRx Co., Ltd, Annual General Meeting, Mar 30, 2022.お知らせ • Jun 04MedRx Co., Ltd announced that it has received ¥552.489 million in funding from Macquarie Bank Limited, Investment ArmOn June 3, 2021, MedRx Co., Ltd (TSE:4586) closed the transaction. The company issued 40 Series 2 Unsecured Bonds at a price of ¥13,750,000 for gross proceeds of ¥550,000,000.お知らせ • May 19MedRx Co., Ltd announced that it expects to receive ¥2.489 million in funding from Macquarie Bank Limited, Investment ArmMedRx Co., Ltd (TSE:4586) announced a private placement of 30,000 series 20 warrants at a price of ¥57 each for gross proceeds of ¥1,710,000 and 19,000 series 21 warrants at a price of ¥41 per share for gross proceeds of ¥779,000? for aggregate gross proceeds of ¥2,489,000 on May 18, 2021. The company will issue securities through third party allotment method to Macquarie Bank Limited, Investment Arm. The series 20 warrants at exercisable at a minimum price of ¥223 and series 21 Warrants for ¥330.Reported Earnings • Apr 04Full year 2020 earnings released: JP¥68.57 loss per share (vs JP¥134 loss in FY 2019)Full year 2020 results: Net loss: JP¥1.11b (loss narrowed 31% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 14Full year 2020 earnings released: JP¥68.57 loss per share (vs JP¥134 loss in FY 2019)Full year 2020 results: Net loss: JP¥1.11b (loss narrowed 31% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 26, 2021MedRx Co., Ltd, Annual General Meeting, Mar 26, 2021.Is New 90 Day High Low • Feb 12New 90-day high: JP¥291The company is up 19% from its price of JP¥244 on 13 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Is New 90 Day High Low • Jan 21New 90-day high: JP¥272The company is up 2.0% from its price of JP¥267 on 23 October 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.お知らせ • Dec 30MedRx Co., Ltd to Report Fiscal Year 2020 Results on Feb 10, 2021MedRx Co., Ltd announced that they will report fiscal year 2020 results on Feb 10, 2021Is New 90 Day High Low • Dec 09New 90-day low: JP¥228The company is down 23% from its price of JP¥297 on 10 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.お知らせ • Aug 14MedRx Co., Ltd announced that it has received ¥206.406 million in funding from Japan International Partners LLCOn August 13, 2020, MedRx Co., Ltd (TSE:4586) closed the transaction.株主還元4586JP PharmaceuticalsJP 市場7D8.2%3.6%2.1%1Y-24.3%16.6%44.1%株主還元を見る業界別リターン: 4586過去 1 年間で16.6 % の収益を上げたJP Pharmaceuticals業界を下回りました。リターン対市場: 4586は、過去 1 年間で44.1 % のリターンを上げたJP市場を下回りました。価格変動Is 4586's price volatile compared to industry and market?4586 volatility4586 Average Weekly Movement7.0%Pharmaceuticals Industry Average Movement5.2%Market Average Movement4.3%10% most volatile stocks in JP Market9.2%10% least volatile stocks in JP Market2.1%安定した株価: 4586の株価は、 JP市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 4586の 週次ボラティリティ は過去 1 年間で15%から7%に減少しましたが、依然としてJP株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200221Yonehiro Matsumurawww.medrx.co.jp製剤開発会社であるメドレックス株式会社は、経皮吸収型医薬品を日本で提供している。同社は、イオン液体経皮吸収システム（ILTS）およびナノサイズコロイド経皮吸収システム（NCTS）をベースとした経皮吸収型医薬品の開発、ワクチンや原薬を皮膚から送達するためのマイクロニードルアレイ／パッチワクチンの開発を行っている。また、神経因性疼痛を適応症として米国で承認申請中のMRX-5LBT、痙性麻痺を適応症として第Ⅱ相試験中のMRX-4TZT、統合失調症を適応症として第Ⅱ相試験中のAlto-101、中等度から重度の疼痛を適応症として第Ⅰ相試験中のMRX-9FLT、慢性疼痛を適応症として製剤開発中のMRX-6LDTなどの製品がある。メドレックス株式会社は2002年に設立され、東かがわ市に本社を置いている。もっと見るMedRx Co., Ltd 基礎のまとめMedRx の収益と売上を時価総額と比較するとどうか。4586 基礎統計学時価総額JP¥3.15b収益（TTM）-JP¥746.00m売上高(TTM)JP¥131.00m24.0xP/Sレシオ-4.2xPER（株価収益率4586 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4586 損益計算書（TTM）収益JP¥131.00m売上原価JP¥1.00m売上総利益JP¥130.00mその他の費用JP¥876.00m収益-JP¥746.00m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-12.57グロス・マージン99.24%純利益率-569.47%有利子負債／自己資本比率0%4586 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/04 03:02終値2026/07/03 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MedRx Co., Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Kiyokazu YamazakiIchiyoshi Research Institute Inc.Dion Stéfan BüchnerPathology Associates Co., Ltd.
Reported Earnings • May 20First quarter 2026 earnings released: JP¥4.01 loss per share (vs JP¥9.03 loss in 1Q 2025)First quarter 2026 results: JP¥4.01 loss per share (improved from JP¥9.03 loss in 1Q 2025). Net loss: JP¥238.0m (loss narrowed 45% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
New Risk • Mar 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (JP¥128m revenue, or US$813k). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.42b market cap, or US$47.2m).
Reported Earnings • Feb 16Full year 2025 earnings released: JP¥17.44 loss per share (vs JP¥18.54 loss in FY 2024)Full year 2025 results: JP¥17.44 loss per share. Net loss: JP¥937.0m (loss widened 16% from FY 2024).
お知らせ • Feb 13MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026.
お知らせ • Dec 27MedRx Co., Ltd to Report Fiscal Year 2025 Results on Feb 13, 2026MedRx Co., Ltd announced that they will report fiscal year 2025 results on Feb 13, 2026
分析記事 • Dec 01Is MedRx (TSE:4586) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • May 20First quarter 2026 earnings released: JP¥4.01 loss per share (vs JP¥9.03 loss in 1Q 2025)First quarter 2026 results: JP¥4.01 loss per share (improved from JP¥9.03 loss in 1Q 2025). Net loss: JP¥238.0m (loss narrowed 45% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
New Risk • Mar 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (JP¥128m revenue, or US$813k). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.42b market cap, or US$47.2m).
Reported Earnings • Feb 16Full year 2025 earnings released: JP¥17.44 loss per share (vs JP¥18.54 loss in FY 2024)Full year 2025 results: JP¥17.44 loss per share. Net loss: JP¥937.0m (loss widened 16% from FY 2024).
お知らせ • Feb 13MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026.
お知らせ • Dec 27MedRx Co., Ltd to Report Fiscal Year 2025 Results on Feb 13, 2026MedRx Co., Ltd announced that they will report fiscal year 2025 results on Feb 13, 2026
分析記事 • Dec 01Is MedRx (TSE:4586) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
お知らせ • Oct 01MedRx Co., Ltd to Report Q3, 2025 Results on Nov 14, 2025MedRx Co., Ltd announced that they will report Q3, 2025 results on Nov 14, 2025
New Risk • Aug 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (JP¥44m revenue, or US$298k). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (JP¥6.38b market cap, or US$43.3m).
New Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (JP¥44m revenue, or US$300k). Minor Risk Market cap is less than US$100m (JP¥5.18b market cap, or US$35.3m).
New Risk • Aug 10New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: JP¥44m (US$298k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (JP¥44m revenue, or US$298k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (JP¥3.42b market cap, or US$23.1m).
New Risk • Jul 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.9% average weekly change). Minor Risks Revenue is less than US$5m (JP¥259m revenue, or US$1.8m). Market cap is less than US$100m (JP¥3.70b market cap, or US$25.2m).
お知らせ • Jul 02MedRx Co., Ltd to Report Q2, 2025 Results on Aug 08, 2025MedRx Co., Ltd announced that they will report Q2, 2025 results on Aug 08, 2025
お知らせ • Apr 16MedRx Co., Ltd announced that it has received ¥0.8309 million in fundingOn April 16, 2025, MedRx Co., Ltd closed the transaction.
New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (JP¥257m revenue, or US$1.8m). Market cap is less than US$100m (JP¥2.71b market cap, or US$18.5m).
お知らせ • Mar 28MedRx Co., Ltd to Report Q1, 2025 Results on May 09, 2025MedRx Co., Ltd announced that they will report Q1, 2025 results on May 09, 2025
お知らせ • Mar 25MedRx Co., Ltd announced that it expects to receive ¥0.8309 million in fundingMEDRx Co., Ltd. announced a private placement to issue 118,700 units 32nd Series of Stock Acquisition Rights at an issue price of ¥7 per right for gross proceeds of ¥830,900 on March 25, 2025. The transaction will include participation from new investor Long Corridor Alpha Opportunities Master Fund. The transaction has been approved by shareholders, expected to close on April 16, 2025. The initial exercise price will be ¥86. The period will be from April 17, 2025 (inclusive) to April 23, 2026 (inclusive). The allocation will be made through a third-party allocation as follows: LCAO 94,960 units MAP 246 23,740 units. The company has disclosed the issue expenses of ¥12,000,000 and net proceeds of ¥1,009,650,900, total amount of payment of ¥1,021,650,900.
Reported Earnings • Feb 16Full year 2024 earnings released: JP¥18.54 loss per share (vs JP¥26.80 loss in FY 2023)Full year 2024 results: JP¥18.54 loss per share (improved from JP¥26.80 loss in FY 2023). Revenue: JP¥257.0m (up JP¥228.0m from FY 2023). Net loss: JP¥806.0m (loss narrowed 14% from FY 2023). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Feb 14MedRx Co., Ltd, Annual General Meeting, Mar 28, 2025MedRx Co., Ltd, Annual General Meeting, Mar 28, 2025.
お知らせ • Jan 03MedRx Co., Ltd to Report Fiscal Year 2024 Results on Feb 14, 2025MedRx Co., Ltd announced that they will report fiscal year 2024 results on Feb 14, 2025
分析記事 • Sep 04Here's Why We're Not At All Concerned With MedRx's (TSE:4586) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Aug 31MedRx Co., Ltd to Report Q3, 2024 Results on Nov 08, 2024MedRx Co., Ltd announced that they will report Q3, 2024 results on Nov 08, 2024
お知らせ • Jun 28MedRx Co., Ltd to Report Q2, 2024 Results on Aug 09, 2024MedRx Co., Ltd announced that they will report Q2, 2024 results on Aug 09, 2024
分析記事 • May 13Companies Like MedRx (TSE:4586) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Reported Earnings • May 13First quarter 2024 earnings released: JP¥3.33 loss per share (vs JP¥9.59 loss in 1Q 2023)First quarter 2024 results: JP¥3.33 loss per share (improved from JP¥9.59 loss in 1Q 2023). Net loss: JP¥128.0m (loss narrowed 56% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • Apr 05MedRx Co., Ltd to Report Q1, 2024 Results on May 10, 2024MedRx Co., Ltd announced that they will report Q1, 2024 results on May 10, 2024
お知らせ • Feb 11MedRx Co., Ltd, Annual General Meeting, Mar 28, 2024MedRx Co., Ltd, Annual General Meeting, Mar 28, 2024.
お知らせ • Feb 06MedRx Co., Ltd announced that it has received ¥1.9076 million in funding from Evolution Capital Management LLCOn February 5, 2024, MedRx Co., Ltd, closed the transaction.
お知らせ • Dec 28MedRx Co., Ltd to Report Fiscal Year 2023 Results on Feb 09, 2024MedRx Co., Ltd announced that they will report fiscal year 2023 results on Feb 09, 2024
New Risk • Oct 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m (JP¥56m revenue, or US$374k). Minor Risk Market cap is less than US$100m (JP¥5.14b market cap, or US$34.4m).
お知らせ • Oct 05MedRx Co., Ltd to Report Q3, 2023 Results on Nov 10, 2023MedRx Co., Ltd announced that they will report Q3, 2023 results on Nov 10, 2023
New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Revenue is less than US$1m (JP¥56m revenue, or US$384k). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (43% increase in shares outstanding). Market cap is less than US$100m (JP¥6.27b market cap, or US$43.0m).
Reported Earnings • Aug 12Second quarter 2023 earnings released: JP¥5.60 loss per share (vs JP¥7.52 loss in 2Q 2022)Second quarter 2023 results: JP¥5.60 loss per share. Net loss: JP¥191.0m (loss widened 3.2% from 2Q 2022).
お知らせ • Jun 28MedRx Co., Ltd to Report Q2, 2023 Results on Aug 10, 2023MedRx Co., Ltd announced that they will report Q2, 2023 results on Aug 10, 2023
Reported Earnings • May 17First quarter 2023 earnings released: JP¥9.59 loss per share (vs JP¥7.97 loss in 1Q 2022)First quarter 2023 results: JP¥9.59 loss per share (further deteriorated from JP¥7.97 loss in 1Q 2022). Net loss: JP¥290.0m (loss widened 48% from 1Q 2022). Revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 31Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: JP¥43.80 loss per share. Net loss: JP¥1.11b (loss widened 4.9% from FY 2021). Revenue missed analyst estimates by 82%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Japan.
Reported Earnings • Feb 12Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: JP¥43.80 loss per share. Net loss: JP¥1.11b (loss widened 4.9% from FY 2021). Revenue missed analyst estimates by 82%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Pharmaceuticals industry in Japan.
お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 29, 2023MedRx Co., Ltd, Annual General Meeting, Mar 29, 2023.
お知らせ • Dec 28MedRx Co., Ltd to Report Fiscal Year 2022 Results on Feb 10, 2023MedRx Co., Ltd announced that they will report fiscal year 2022 results on Feb 10, 2023
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (6 non-independent directors). Independent External Director Kunio Iwatani was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 13Third quarter 2022 earnings released: JP¥10.32 loss per share (vs JP¥9.21 loss in 3Q 2021)Third quarter 2022 results: JP¥10.32 loss per share (further deteriorated from JP¥9.21 loss in 3Q 2021). Net loss: JP¥254.0m (loss widened 25% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • Sep 28MedRx Co., Ltd to Report Q3, 2022 Results on Nov 11, 2022MedRx Co., Ltd announced that they will report Q3, 2022 results on Nov 11, 2022
お知らせ • Aug 24MedRx Co., Ltd announced that it expects to receive ¥3.904 million in fundingMedRx Co., Ltd announced a private placement of 61,000 series 24 warrants at a price of ¥64 each for gross proceeds of ¥3,904,000. The series 24 warrants at exercisable at a minimum price of ¥64.
Reported Earnings • Aug 12Second quarter 2022 earnings released: JP¥7.52 loss per share (vs JP¥10.61 loss in 2Q 2021)Second quarter 2022 results: JP¥7.52 loss per share (up from JP¥10.61 loss in 2Q 2021). Net loss: JP¥185.0m (loss narrowed 12% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • May 30MedRx Co., Ltd to Report Q2, 2022 Results on Aug 10, 2022MedRx Co., Ltd announced that they will report Q2, 2022 results on Aug 10, 2022
Reported Earnings • May 19First quarter 2022 earnings released: JP¥7.97 loss per share (vs JP¥13.32 loss in 1Q 2021)First quarter 2022 results: JP¥7.97 loss per share (up from JP¥13.32 loss in 1Q 2021). Net loss: JP¥196.0m (loss narrowed 25% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (6 non-independent directors). Independent External Director Kunio Iwatani was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 08MedRx Co., Ltd to Report Q1, 2022 Results on May 13, 2022MedRx Co., Ltd announced that they will report Q1, 2022 results on May 13, 2022
お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 30, 2022MedRx Co., Ltd, Annual General Meeting, Mar 30, 2022.
お知らせ • Jun 04MedRx Co., Ltd announced that it has received ¥552.489 million in funding from Macquarie Bank Limited, Investment ArmOn June 3, 2021, MedRx Co., Ltd (TSE:4586) closed the transaction. The company issued 40 Series 2 Unsecured Bonds at a price of ¥13,750,000 for gross proceeds of ¥550,000,000.
お知らせ • May 19MedRx Co., Ltd announced that it expects to receive ¥2.489 million in funding from Macquarie Bank Limited, Investment ArmMedRx Co., Ltd (TSE:4586) announced a private placement of 30,000 series 20 warrants at a price of ¥57 each for gross proceeds of ¥1,710,000 and 19,000 series 21 warrants at a price of ¥41 per share for gross proceeds of ¥779,000? for aggregate gross proceeds of ¥2,489,000 on May 18, 2021. The company will issue securities through third party allotment method to Macquarie Bank Limited, Investment Arm. The series 20 warrants at exercisable at a minimum price of ¥223 and series 21 Warrants for ¥330.
Reported Earnings • Apr 04Full year 2020 earnings released: JP¥68.57 loss per share (vs JP¥134 loss in FY 2019)Full year 2020 results: Net loss: JP¥1.11b (loss narrowed 31% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 14Full year 2020 earnings released: JP¥68.57 loss per share (vs JP¥134 loss in FY 2019)Full year 2020 results: Net loss: JP¥1.11b (loss narrowed 31% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
お知らせ • Feb 12MedRx Co., Ltd, Annual General Meeting, Mar 26, 2021MedRx Co., Ltd, Annual General Meeting, Mar 26, 2021.
Is New 90 Day High Low • Feb 12New 90-day high: JP¥291The company is up 19% from its price of JP¥244 on 13 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Jan 21New 90-day high: JP¥272The company is up 2.0% from its price of JP¥267 on 23 October 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.
お知らせ • Dec 30MedRx Co., Ltd to Report Fiscal Year 2020 Results on Feb 10, 2021MedRx Co., Ltd announced that they will report fiscal year 2020 results on Feb 10, 2021
Is New 90 Day High Low • Dec 09New 90-day low: JP¥228The company is down 23% from its price of JP¥297 on 10 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
お知らせ • Aug 14MedRx Co., Ltd announced that it has received ¥206.406 million in funding from Japan International Partners LLCOn August 13, 2020, MedRx Co., Ltd (TSE:4586) closed the transaction.
